MRI disease activity significantly reduced with remibrutinib vs. teriflunomide in two trials, including reductions in T2 lesion activity by 65% and 70%, and Gd+ T1 lesions by 66% across both trials¹ ...
Afrique du Sud Albanie Algérie Allemagne Ancienne république yougoslave de Macédoine Argentine Arménie Australie Autriche Bahamas Barbade Belgique Bénin Bermudes Bolivie Bosnie-Herzégovine Brésil ...
Explore opportunities with Novartis below.
Health doesn't only begin in hospitals and clinics. It can often start wherever people gather and trust one another. That's why Novartis and the Novartis Foundation work alongside local partners to ...
ノバルティスについて 患者さんと一般の方向け 医療関係者向け情報 研究開発 ESG（環境・社会・ガバナンス） ニュース 採用情報 お問い合わせ ノバルティス社員の安否確認窓口 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results